Gastroenterology and Food and Drug Administration

Selected news for the healthcare topic - Gastroenterology, and the healthcare topic - Food and Drug Administration. We have 34 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
8/17/2021 Eli Lilly to form Neuroscience and Immunology business units ... Food and Drug Administration. Eli Lilly said Patrik Jonsson, who currently serves as senior vice president, president of Lilly USA and chief customer officer, would take on the additional post of president of Lilly Immunology, overseeing the company‚Aos launched products and Phase 3 portfolio of medicines in dermatology, gastroenterology and rheumatology. Eli Lilly said the changes are effective Sept. 5. Write to Colin Kellaher at [email protected] News Highlights ...
7/22/2021 Menarini Asia-Pacific strengthens Men's Health portfolio in China with acquisition of Cialis(R) (Tadalafil) from Lilly Yahoo News ... marketing and distribution responsibilities.Cialis® was first approved by the European Medicines Agency in 2002 followed by the U.S. Food and Drug Administration ("FDA") in 2003 and then NMPA (National Medical Products Administration) in ... focused on major therapeutic categories including Dermatology, Allergy/Respiratory, Cardiovascular, Gastroenterology, Pain Management, Consumer Healthcare, Oncology and Anti-Infectives.Maurizio Luongo , Chief Executive Officer, Menarini Asia-Pacific said, "The acquisition of Cialis® is a ...
4/8/2021 Lawsuits & expansions: 7 anesthesia updates Becker's ASC Review ... gastroenterology-focused anesthesia practice.5. Melville, N.Y.-based North American Partners in Anesthesia is expanding anesthesia services to more Virginia patients through its partnership with Bon Secours-Richmond (Va.), a subsidiary of Bon Secours Mercy Health.6. The Food and Drug Administration approved Pacira's supplemental new drug application to expand the use of its long-acting local anesthetic, Exparel, in children.7. NorthStar Anesthesia began providing services at Baptist Health ...
4/1/2021 The Endoscope Repair Market To Attain A Healthy Resolution Between 2025 PRSync The Endoscope Repair Market To Attain A Healthy Resolution Between 2025 persistencemarketresearch - Thursday, April 1, 2021.Increasing demand for endoscopic procedures, owing to its benefits of being a minimally invasive procedure, is anticipated to boost growth of the global endoscope repair market . Guidelines published by several government authorities, including the Food and Drug Administration (FDA), Society of Gastroenterology Nurses and Associates (SGNA), Centers for Disease Control and Prevention (CDC), and ...
3/27/2021 Global Medical Device Reprocessing Market worth USD 1,754 Million : Increasing Use of Cardiology and Gastroenterology Global Medical Device Reprocessing Market worth USD 1,754 Million : Increasing Use of Cardiology and Gastroenterology medical device reprocessing market is projected to be valued at USD 823.5 Million in 2017 and is expected to grow ... report is 2016.Various secondary sources such as associations (including Food and Drug Administration (FDA), European Association for Medical Device Reprocessing (EAMDR), Association of Medical Device Reprocessors (AMDR), and Canadian Association of Medical Device Reprocessing ...
1/2/2021 3 Unhealthy Yogurt Ingredients and Mistakes to Avoid | Livestrong.com ... Food and Drug Administration ‚Aa . ‚Aa Additional strains can be added but these two must be present.That's good news for our guts because these two probiotic strains have been linked to improved lactose digestion and a reduced risk of both diarrhea and constipation, per the World Gastroenterology Organization . The beneficial bacteria are also linked to helping conditions like irritable bowel syndrome (IBS) and irritable bowel disease (IBD).Knowing these ...
10/2/2020 Real-world safety, efficacy found for fecal transplants ... Gastroenterology could allay concerns about a treatment that has yet to gain full approval by the Food and Drug Administration, despite successful clinical trials. C. diff infections are common and increasing in the United States, often can’t be cured with conventional treatments such as antibiotics, and can be deadly. Transplanting fecal matter from a donor to the patient appears to work by restoring beneficial microorganisms to the patient’s gut. The ...
10/1/2020 Delayed Healing of Tooth Extraction Sockets with Ramucirumab Use ... progression by blocking the nutritional supply that the tumor requires. Ramucirumab, which was relatively newly approved by the United States Food and Drug Administration, binds to the extracellular domain of vascular endothelial growth factor-2 ... man was referred to the oral surgery clinic from the gastroenterology and hepatology clinic for dental caries treatment. In August 2016, the patient was diagnosed with gastric cancer with multiple liver metastases and lymph node ...
10/1/2020 September 2020 Briefing ... for repeat colonoscopy as well as the proper surveillance interval, according to a study recently published in the Journal of Gastroenterology and Digestive Systems . Abstract/Full Text (subscription or payment may be required) COVID-19 ... may be linked to a multistate Salmonella outbreak, the U.S. Food and Drug Administration said Thursday. More Information FDA: Mercury Risk Means Certain People Should Not Get Amalgam Dental Fillings FRIDAY, Sept. 25, 2020 -- Certain ...
9/29/2020 FDA authorizes new IND to evaluate impact of multi-strain probiotic DS-01™ on gut microbiota of patients with IBS PR Newswire BOSTON , Sept. 29, Seed Health, a microbial sciences company, today announced U.S. Food and Drug Administration (FDA) authorization of its Investigational New Drug (IND) application for DS-01 ™ , a broad spectrum multi-species, multi-strain ... led by gastroenterologist Dr. Anthony Lembo , of the Division of Gastroenterology, Hepatology and Nutrition at Beth Israel Deaconess Medical Center, will use novel functional biomarkers to understand the role of the host microbiota in IBS ...
9/22/2020 Bausch Health And Alfasigma Announce Resolution Of XIFAXAN® Intellectual Property Litigation PR Newswire ... QC , Sept. 22, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") along with its gastroenterology business, Salix Pharmaceuticals ("Salix"), which is one of the largest specialty pharmaceutical companies in ... 550 mg tablets, should it receive approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application. Litigation between the parties related to XIFAXAN will be dismissed, and all intellectual Property ...
9/21/2020 DuPont Human Microbiome Venture and Procter & Gamble Enter Research Collaboration in Next Generation Probiotics PRWeb ... Gastroenterology 2012; 143:913–916. ³ Among Gastroenterologists who recommended a brand of probiotic in a ProVoice 2008-2019 survey. Among Doctors who recommended a brand of probiotic in ProVoice 2013-2019 surveys. ⁴ These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. About P&G P&G serves consumers around the world with one of the ...
9/17/2020 FDA Compares Performance of COVID-19 Diagnostic Tests Medscape ... September 17, 2020 Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The US Food and Drug Administration (FDA) revealed comparative performance data for 55 molecular diagnostic COVID-19 ... covers a wide range of medical specialties, including infectious diseases, gastroenterology and dermatology. Follow Damian on Twitter: @MedReporter . For more news, follow Medscape on Facebook , Twitter , Instagram , and YouTube. Medscape Medical News © 2020 ...
9/14/2020 Mallinckrodt Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Hepatorenal Syndrome Type 1 (HRS-1) PR Newswire Mallinckrodt Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Hepatorenal Syndrome Type 1 (HRS-1) Company remains committed to working with FDA toward an approval for this important potential therapy News provided by Sep 14, 2020, 06:45 ET Share this article DUBLIN , Sept. 14, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK ), a global biopharmaceutical company, today announced that the U.S ...
9/11/2020 Southern California Research Institute Receives FDA Greenlight for Ivermectin Clinical Trial Sep 10, 2020 COVID-19 , Hydroxychloroquine , Investor Watch , Ivermectin , News , Popular Posts , Progenabiome LLC California’s ProgenaBiome recently received the greenlight from the U.S. Food and Drug Administration (FDA) for two Phase 2 clinical trials involving investigational therapies targeting COVID-19: one of them based on hydroxychloroquine and the other ivermectin. With approved investigational new drug (IND) applications, a dynamic and accomplished California gastroenterology principal investigator, Dr. Sabine Hazan, and team ...
9/10/2020 Theratechnologies to Develop Tesamorelin for the Treatment of NASH in the General Population Globe Newswire ... Gastroenterology, and Adjunct Professor in the Division of Epidemiology at the University of California, San Diego. Phase 3 clinical trial Theratechnologies intends to submit its Phase 3 study protocol to the United States Food and Drug Administration (FDA) and the European regulatory agencies in the coming weeks. Subject to feedback from the regulatory agencies, the trial would involve approximately 650 patients with fibrosis scores of 2 and 3 and with ...
7/24/2020 BREZTRI AEROSPHERE approved in the US for the maintenance treatment of COPD Business Wire ... in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The approval by the US Food and Drug Administration (FDA) was based on positive results from the Phase III ETHOS ... potential, in areas including rheumatology (including systemic lupus erythematosus), dermatology, gastroenterology, and systemic eosinophilic-driven diseases. AstraZeneca’s ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide. AstraZeneca ...
7/21/2020 9 Meters Biopharma, Inc. Doses the First Patients in Phase 1b/2a Clinical Trial in Short Bowel Syndrome - GuruFocus.com ... RALEIGH, NC / ACCESSWIRE / July 21, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today that the first patients have been dosed in a Phase 1b ... study and has been granted Orphan Designation by the U.S. Food and Drug Administration. "9 Meters seeks to offer a therapeutic option for SBS patients that mitigates reliance on parenteral support, and minimizes the frequency ...
7/17/2020 Ambu Receives FDA Clearance for Its Sterile, Single-Use Duodenoscope Business Wire ... of sterile, single-use endoscopes, announced today that the Ambu® aScope™ Duodeno has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This press release features multimedia. View the full release here ... our sales organization and built a dedicated commercial infrastructure for gastroenterology. After today’s FDA clearance, we will now approach our customers to arrange product demonstrations, set up evaluations and promote what Ambu has to offer ...
7/13/2020 FDA grants authorization for Individual Patient Expanded Access Protocol for the use of tradipitant for gastroparesis PR Newswire ... ET Share this article WASHINGTON , July 13, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) announced today that the U.S. Food and Drug Administration (FDA) has authorized a single patient in an Individual Patient Expanded ... effectively managed the patient's gastroparesis symptoms. The FDA's Division of Gastroenterology has authorized expanded access to tradipitant for this patient for an additional 6 months under this protocol with the potential to renew upon written ...
6/26/2020 Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol PR Newswire ... biotechnology company developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter to the Biologics License ... areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on ...
6/23/2020 Ortho Dermatologics Launches ARAZLO™ (tazarotene) Lotion, 0.045%, In The United States - PRNewswire PR Newswire ... tazarotene) Lotion, 0.045%, is available commercially to health care professionals in the United States this week. Approved by the U.S. Food and Drug Administration (FDA) in December 2019 , ARAZLO is the first tazarotene acne treatment ... counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found ...
6/22/2020 FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity PR Newswire NORTH CHICAGO, Ill. - Allergan, an AbbVie (NYSE: ABBV ) company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental biologics license application (sBLA) to expand the BOTOX ® prescribing information for ... areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on ...
6/19/2020 FDA Approves Evoke’s GIMOTI™ Globe Newswire ... Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for GIMOTI™ (metoclopramide ... Stanley H. Lorber Research Endowment Fund and Chair, and Director, Gastroenterology Motility Laboratory, School of Medicine at Temple University. “Unlike oral medications, GIMOTI is administered nasally, bypassing the diseased GI track, allowing the drug to ...
6/19/2020 FDA Approves Gimoti (metoclopramide) Nasal Spray for Diabetic Gastroparesis ... Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Gimoti (metoclopramide ... Stanley H. Lorber Research Endowment Fund and Chair, and Director, Gastroenterology Motility Laboratory, School of Medicine at Temple University. “Unlike oral medications, Gimoti is administered nasally, bypassing the diseased GI track, allowing the drug to ...